

**TOXICOLOGICAL PROFILE FOR  
DIISOPROPYL METHYLPHOSPHONATE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

**August 1998**

**DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

### **UPDATE STATEMENT**

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Claire V. Broome, M.D.  
Acting Administrator  
Agency for Toxic Substances and  
Disease Registry

### \*Legislative Background

The toxicological profiles are developed in response to the Super-fund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Super-fund). Section 211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities. Section 2704(b) of Title 10 of the U. S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological profile for each substance on the list provided by the Secretary of Defense under subsection (b).

**CONTRIBUTORS****CHEMICAL MANAGER(S)/AUTHOR(S):**

Malcolm Williams, Ph.D.  
ATSDR, Division of Toxicology, Atlanta, GA

Diana Wong, Ph.D., DABT  
Sciences International, Inc., Alexandria, VA

Patricia M. Bittner, M.S.  
Sciences International, Inc., Alexandria, VA

Steve Rhodes, Ph.D.  
Sciences International, Inc., Alexandria, VA

**THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:**

1. Green Border Review. Green Border review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.





## PEER REVIEW

A peer review panel was assembled for diisopropyl methylphosphonate. The panel consisted of the following members:

1. Dr. Arthur Gregory, Private Consultant, Sterling, VA
2. Dr. Rudy Jaeger, President and Principal Scientist, Environmental Medicine, Inc., Westwood, NJ
3. Dr. Norbert Page, Private Consultant, Gaithersburg, MD

These experts collectively have knowledge of diisopropyl methylphosphonate's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
PEER REVIEW .....	ix
LIST OF FIGURES .....	xv
LIST OF TABLES .....	xvii
<b>1. PUBLIC HEALTH STATEMENT .....</b>	<b>1</b>
1.1 WHAT IS DIISOPROPYL METHYLPHOSPHONATE? .....	1
1.2 WHAT HAPPENS TO DIISOPROPYL METHYLPHOSPHONATE WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO DIISOPROPYL METHYLPHOSPHONATE? .....	3
1.4 HOW CAN DIISOPROPYL METHYLPHOSPHONATE ENTER AND LEAVE MY BODY? .....	3
1.5 HOW CAN DIISOPROPYL METHYLPHOSPHONATE AFFECT MY HEALTH? .....	4
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO DIISOPROPYL METHYLPHOSPHONATE? .....	5
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	5
1.8 WHERE CAN I GET MORE INFORMATION? .....	6
<b>2. HEALTH EFFECTS .....</b>	<b>9</b>
2.1 INTRODUCTION .....	9
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	9
2.2.1 Inhalation Exposure .....	11
2.2.1.1 Death .....	11
2.2.1.2 Systemic Effects .....	11
2.2.1.3 Immunological and Lymphoreticular Effects .....	11
2.2.1.4 Neurological Effects .....	11
2.2.1.5 Reproductive Effects .....	11
2.2.1.6 Developmental Effects .....	11
2.2.1.7 Genotoxic Effects .....	11
2.2.1.8 Cancer .....	11
2.2.2 Oral Exposure .....	11
2.2.2.1 Death .....	24
2.2.2.2 Systemic Effects .....	28
2.2.2.3 Immunological and Lymphoreticular Effects .....	37
2.2.2.4 Neurological Effects .....	38
2.2.2.5 Reproductive Effects .....	40
2.2.2.6 Developmental Effects .....	42
2.2.2.7 Genotoxic Effects .....	43
2.2.2.8 Cancer .....	43

2.2.3	Dermal Exposure	43
2.2.3.1	Death	43
2.2.3.2	Systemic Effects	45
2.2.3.3	Immunological and Lymphoreticular Effects	46
2.2.3.4	Neurological Effects	46
2.2.3.5	Reproductive Effects	46
2.2.3.6	Developmental Effects	46
2.2.3.7	Genotoxic Effects	46
2.2.3.8	Cancer	46
2.3	TOXICOKINETICS	46
2.3.1	Absorption	47
2.3.1.1	Inhalation Exposure	47
2.3.1.2	Oral Exposure	47
2.3.1.3	Dermal Exposure	48
2.3.2	Distribution	49
2.3.2.1	Inhalation Exposure	49
2.3.2.2	Oral Exposure	49
2.3.2.3	Dermal Exposure	50
2.3.3	Metabolism	51
2.3.4	Elimination and Excretion	52
2.3.4.1	Inhalation Exposure	52
2.3.4.2	Oral Exposure	52
2.3.4.3	Dermal Exposure	53
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	54
2.4	MECHANISMS OF ACTION	55
2.4.1	Pharmacokinetic Mechanisms	55
2.4.2	Mechanisms of Toxicity	58
2.4.3	Animal-to-Human Extrapolations	59
2.5	RELEVANCE TO PUBLIC HEALTH	59
2.6	BIOMARKERS OF EXPOSURE AND EFFECT	74
2.6.1	Biomarkers Used to Identify or Quantify Exposure to Diisopropyl Methylphosphonate	77
2.6.2	Biomarkers Used to Characterize Effects Caused by Diisopropyl Methylphosphonate	78
2.7	INTERACTIONS WITH OTHER SUBSTANCES	78
2.8	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	78
2.9	METHODS FOR REDUCING TOXIC EFFECTS	79
2.9.1	Reducing Peak Absorption Following Exposure	79
2.9.2	Reducing Body Burden	80
2.9.3	Interfering with the Mechanism of Action for Toxic Effects	80
2.10	ADEQUACY OF THE DATABASE	80
2.10.1	Existing Information on Health Effects of Diisopropyl Methylphosphonate	81
2.10.2	Identification of Data Needs	81
2.10.3	On-going Studies	86
3.	CHEMICAL AND PHYSICAL INFORMATION	87
3.1	CHEMICAL IDENTITY	87
3.2	PHYSICAL AND CHEMICAL PROPERTIES	87

4. PRODUCTION, IMPORT, USE, AND DISPOSAL .....	91
4.1 PRODUCTION .....	91
4.2 IMPORT/EXPORT .....	91
4.3 USE .....	92
4.4 DISPOSAL .....	92
5. POTENTIAL FOR HUMAN EXPOSURE .....	95
5.1 OVERVIEW .....	95
5.2 RELEASES TO THE ENVIRONMENT .....	97
5.2.1 Air .....	97
5.2.2 Water .....	97
5.2.3 Soil .....	98
5.3 ENVIRONMENTAL FATE .....	99
5.3.1 Transport and Partitioning .....	99
5.3.2 Transformation and Degradation .....	100
5.3.2.1 Air .....	100
5.3.2.2 Water .....	100
5.3.2.3 Sediment and Soil .....	101
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	101
5.4.1 Air .....	101
5.4.2 Water .....	101
5.4.3 Sediment and Soil .....	102
5.4.4 Other Environmental Media .....	103
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	103
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	103
5.7 ADEQUACY OF THE DATABASE .....	103
5.7.1 Identification of Data Needs .....	104
5.7.2 On-going Studies .....	106
6. ANALYTICAL METHODS .....	107
6.1 BIOLOGICAL SAMPLES .....	107
6.2 ENVIRONMENTAL SAMPLES .....	108
6.3 ADEQUACY OF THE DATABASE .....	114
6.3.1 Identification of Data Needs .....	115
6.3.2 On-going Studies .....	115
7. REGULATIONS AND ADVISORIES .....	117
8. REFERENCES .....	121
9. GLOSSARY .....	131

APPENDICES

A. MINIMAL RISK LEVEL WORKSHEET ..... A-1

B. USER'S GUIDE ..... B-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ..... C-1

## LIST OF FIGURES

2-1	Levels of Significant Exposure to Diisopropyl Methylphosphonate - Oral .....	20
2-2	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	56
2-3	Existing Information on Health Effects of Diisopropyl Methylphosphonate .....	82
5-1	Frequency of NPL Sites with Diisopropyl Methylphosphonate Contamination .....	96





**LIST OF TABLES**

2-1	Levels of Significant Exposure to Diisopropyl Methylphosphonate - Oral .....	12
2-2	Levels of Significant Exposure to Diisopropyl Methylphosphonate - Dermal .....	44
2-3	Genotoxicity of Diisopropyl Methylphosphonate <i>In Vivo</i> .....	75
2-4	Genotoxicity of Diisopropyl Methylphosphonate <i>In Vitro</i> .....	76
3-1	Chemical Identity of Diisopropyl Methylphosphonate .....	88
3-2	Physical and Chemical Properties of Diisopropyl Methylphosphonate .....	89
6-1	Analytical Methods for Determining Diisopropyl Methylphosphonate in Biological Samples .....	109
6-2	Analytical Methods for Determining Diisopropyl Methylphosphonate in Environmental Samples ..	111
7-1	Regulations and Guidelines Applicable to Diisopropyl Methylphosphonate .....	118

